Results 61 to 70 of about 103,961 (275)

Randomized phase II study of consolidation immunotherapy with nivolumab and ipilimumab or nivolumab alone following concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small-cell lung cancer (NSCLC): Big Ten Cancer Research Consortium LUN16-081

Journal for ImmunoTherapy of Cancer
Background For unresectable stage III non-small-cell lung cancer (NSCLC), the optimal duration and regimen of consolidation immunotherapy following chemoradiation is unknown.
Borys Hrinczenko, Jarushka Naidoo, Jason Chesney, Salma K Jabbour, Naomi Fujioka, Greg Durm, Apar Kishor Ganti, Hirva Mamdani, Mary Jo Fidler, Nasser H Hanna, Shadia Jalal, Ticiana A Leal, Sandra Althouse, Susan Perkins, Lawrence Feldman   +14 more
doaj   +1 more source

Radiotherapy is an independent prognostic marker of favorable prognosis in non‐small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab

Thoracic Cancer, 2019
Background It remains unclear why radiation clinically provides a synergistic effect when combined with immune checkpoint inhibitors such as nivolumab. The purpose of our study was to retrospectively evaluate whether the therapeutic efficacy of nivolumab
Ou Yamaguchi, Kyoichi Kaira, Kosuke Hashimoto, Atsuto Mouri, Yu Miura, Ayako Shiono, Fuyumi Nishihara, Yoshitake Murayama, Shin‐ei Noda, Shingo Kato, Kunihiko Kobayashi, Hiroshi Kagamu   +11 more
doaj   +1 more source

Nivolumab-induced immune thrombocytopenia in a patient with malignant pleural mesothelioma

Respiratory Medicine Case Reports, 2020
Malignant pleural mesothelioma (MPM) is a rare and highly aggressive tumor. Nivolumab showed durable antitumor effect in patients with recurrent MPM and was approved for those patients in Japan in 2018.
Jun Sakakibara-Konishi, Mineyoshi Sato, Michiko Takimoto Sato, Kohei Kasahara, Masahiro Onozawa, Hidenori Mizugaki, Eiki Kikuchi, Hajime Asahina, Naofumi Shinagawa, Satoshi Konno   +9 more
doaj   +1 more source

Neurological complications of immune checkpoint inhibitors: what happens when you \u27take the brakes off\u27 the immune system. [PDF]

, 2018
Patients with advanced malignancies treated with immune checkpoint inhibitors are at increased risk for developing immune-related neurological complications.
Dalakas, Marinos
core   +1 more source

Vorinostat Potentiates Chemoimmunotherapy in Immune‐Enriched Pancreatic Cancer

Advanced Science, EarlyView.
Immune‐enriched pancreatic cancer does not confer a significant survival advantage. SAHA sensitizes these “hot” tumors to chemoimmunotherapy by disrupting a FASN/PARP9‐driven “metabolic trap” and enhancing CD8+ T cell function. A CD8high/FASNhigh/PARP9high signature identifies patients who are most likely to benefit from the “gemcitabine‐nivolumab‐SAHA”
Chen Chen, Dingru Li, Yingna Liao, Zehua Wang, Chunbin Zhu, Zifeng Zhang, Liquan Jin, Yueyue Chen, Jiaoshun Chen, Junyi Xu, Miaoyan Wei, Rong Tang, Xianjun Yu, Si Shi   +13 more
wiley   +1 more source

Response to first line chemotherapy regimen is associated with efficacy of nivolumab in non-small-cell lung cancer

OncoImmunology, 2017
Nivolumab, an anti PD-1 checkpoint inhibitor has demonstrated efficacy in metastatic non-small-cell lung cancer (NSCLC) patients after failure to standard chemotherapy. Standard chemotherapy agents could promote antitumor immune response.
Courèche-Guillaume Kaderbhai, Corentin Richard, Jean David Fumet, Anne Aarnink, Sandra Ortiz-Cuaran, Maurice Pérol, Pascal Foucher, Bruno Coudert, Laure Favier, Aurélie Lagrange, Emeric Limagne, Romain Boidot, Sylvain Ladoire, Michel Poudenx, Marius Ilie, Paul Hofman, Pierre Saintigny, François Ghiringhelli   +17 more
doaj   +1 more source

Regorafenib Versus Nivolumab After Sorafenib Failure: Real‐World Data in Patients With Hepatocellular Carcinoma

Hepatology Communications, 2020
Regorafenib and nivolumab are drugs approved for second‐line treatment of patients with hepatocellular carcinoma (HCC) after sorafenib failure. However, the effectiveness of regorafenib and nivolumab following sorafenib has not been directly compared ...
Won‐Mook Choi, Jonggi Choi, Danbi Lee, Ju Hyun Shim, Young‐Suk Lim, Han Chu Lee, Young‐Hwa Chung, Young‐Sang Lee, Sook Ryun Park, Min‐Hee Ryu, Baek‐Yeol Ryoo, So Jung Lee, Kang Mo Kim   +12 more
doaj   +1 more source

Recurrent gastric cancer sustaining a partial response after the nivolumab discontinuation because of immune-related adverse events: a case report

Surgical Case Reports, 2020
Background The prognosis of patients with recurrent gastric cancer is poor despite chemotherapy being clinically recommended as the first therapeutic strategy.
Takaaki Arigami, Daisuke Matsushita, Keishi Okubo, Takako Tanaka, Ken Sasaki, Masahiro Noda, Yoshiaki Kita, Shinichiro Mori, Yusuke Tsuruda, Hiroshi Kurahara, Takao Ohtsuka   +10 more
doaj   +1 more source

Bilateral Sensorineural Hearing Loss Associated With Nivolumab Therapy for Stage IV Malignant Melanoma

Ear, Nose & Throat Journal, 2021
Objectives: Present the case of a 67-year-old male with stage IV malignant melanoma who presented with uveitis and sensorineural hearing loss (SNHL) while on nivolumab and review the literature for likely etiologies.
Alex J. F. Tampio MD, Swetha Dhanireddy MD, Abirami Sivapiragasam MD, Brian D. Nicholas MD   +3 more
doaj   +1 more source

Biological therapy in the treatment of melanoma [PDF]

, 2018
Melanoma is one of the most aggressive tumors and its incidence is on the rise. The low rates of survival in metastatic melanoma has led to the development of new drugs for this type of patient, such as biological therapy which has shown remarkable ...
Benea, Vasile, Georgescu, Simona Roxana, Ghita, Ela, Ioghen, Mihaela Roxana, Ion, Alexandra-Florentina, Mitran, Cristina-Iulia, Mitran, Madalina-Irina, Sarbu, Maria Isabela, Tampa, Mircea   +8 more
core   +3 more sources